 The purpose of this clinical trial is to describe the toxicity, biodistribution, pharmacokinetics and tumour uptake of a single infusion of ch806 tagged with a trace amount of radioactive 111-Indium: 111In-ch806 in patients with advanced tumours expressing the 806 antigen. 